Corporate Overview
Annual Report
News Releases
Stock Quote
Career Opportunities
Our Science
Contact Us
Back to Home Page


Creative BioMolecules, Inc. is a biopharmaceutical company focused on the discovery and development of therapies for human tissue regeneration and repair. The Company's therapies are based on bone morphogenetic proteins (BMPs) that act in initiating and regulating the cellular events involved in the development and repair of human tissues and organs.

Creative BioMolecules' lead product, a bone graft substitute, has completed a U.S. pivotal clinical trial. The bone graft substitute is designed to promote new bone growth to heal severe fractures. Additional products in development include therapies for kidney failure, and stroke and other neurological disorders. The Company’s research focus is also directed toward the discovery of new therapeutic applications of its morphogenic proteins and the understanding of signaling pathways to develop small molecules based on the biology of these proteins.

The Company has a strong portfolio of issued patents and patent applications that provides broad protection for product development with multiple proteins in many therapeutic fields.

Upcoming Events

Creative BioMolecules' participates in numerous scientific and investor conferences. A calendar of upcoming events is available on this site.

Market Data

To view market data on Creative BioMolecules, click on the Nasdaq symbol.



Management Team

President and Chief Executive Officer Michael M. Tarnow
Chief Scientific Officer Charles Cohen, PhD
Vice President, Research and Development Carl M. Cohen, PhD
General Counsel and Vice President, Administration Cheryl K. Lawton
Vice President, Finance and Corporate Development Steven L. Basta

Copyright 1998 Creative BioMolecules, Inc. All Rights Reserved
Last modified: 03/12/99
Important Legal Information